OR WAIT 15 SECS
Bora announced the appointment of Samuel Ricchezza as president of its North American operations.
Contract development and manufacturing organization (CDMO), Bora, has announced the appointment of Samuel Ricchezza as president of its North American operations in a Nov. 19, 2019 press release.
This appointment follows the company’s recent opening of a corporate development office on the Eastern coast of the United States. In the new role, Ricchezza will be tasked with advancing the North American growth of the company and will be responsible for any local acquisition plans.
“We are delighted to have Sam as part of our growing team in the US. He adds invaluable experience and knowledge that will be essential to the success of our two-year expansion plans within the region,” said Bobby Sheng, CEO at Bora Pharmaceuticals, in the press release. “We have an ambitious growth strategy, and I can’t think of a better fit than Sam to propel this forward for our team. As our customers outsource more of their most challenging oral solid dose (OSD) requirements, Sam is also ideally placed to offer the on-hand senior support to help navigate these challenges.”
Ricchezza has more than 25 years’ CDMO experience, joining Bora on the back of being the president for WellSpring Pharma Services. Additionally, he previously held senior roles at companies such as Patheon and AAIPharma (Alcami).
“I was attracted to Bora because of its ability to not only offer custom solutions for complex OSD products but to also facilitate a worldwide business strategy for its customers given its expertise in multiple markets,” added Ricchezza. “Bora’s activity within North America is really exciting, and having supported the sale of WellSpring Pharma Services, I am thrilled to have the opportunity to sit on the other side of the table and advance Bora’s growth strategy in the region.”
Source: Bora Pharmaceuticals